Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Mayo scientists developing at-home swab tests for endometrial, ovarian cancer

Written by | 4 Jun 2024

Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there… read more.

Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer – GSK

Written by | 31 Mar 2024

GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOTEN6/GOG3031/NSGO phase III… read more.

Update on phase III LEAP-001 trial evaluating Keytruda (pembrolizumab) + Lenvima (lenvatinib) as first-line treatment for advanced or recurrent endometrial carcinoma – Merck Inc + Eisai

Written by | 13 Dec 2023

Merck Inc., known as MSD outside of the United States and Canada, and Eisai announced that the Phase III LEAP-001 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima,… read more.

MHRA (UK) approves Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults – GSK

Written by | 11 Oct 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults. It can… read more.

Jemperli + chemotherapy approved by the FDA as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer – GSK

Written by | 3 Aug 2023

GSK plc announced that the FDA has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult… read more.

Novel combination treatment effective in recurrent ER-positive endometrial cancer

Written by | 20 Apr 2022

Researchers from a phase 2 study report that combination treatment with abemaciclib and letrozole shrinks or stabilizes tumors in a majority of subjects diagnosed with recurrent or persistent… read more.

European Commission approves Lenvima + Keytruda to treat endometrial carcinoma – Eisai + Merck Inc.

Written by | 29 Jan 2022

Eisai Co., Ltd. and Merck Inc., announced that the European Commission has approved the combination of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai,… read more.

FDA approves Keytruda + Lenvima to treat advanced endometrial cancer – Merck Inc.+ Eisai

Written by | 15 Aug 2021

The FDA has approved pembrolizumab (Keytruda) in combination with lenvatinib (Lenvima) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),… read more.

FDA grants priority review to Keytruda + Lenvima for advanced endometrial carcinoma – Merck Inc + Eisai

Written by | 20 May 2021

Merck Inc and Eisai announced that the FDA has accepted and granted priority review for an application seeking new approval for the combination of Keytruda (pembrolizumab) plus Lenvima… read more.

Protected: FDA grants accelerated approval for Jemperli in endometrial cancer – GSK

Written by | 1 May 2021

There is no excerpt because this is a protected post.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.